EUVIMEDEUVIMED entdecken
Editorial

PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811

James Yu, Anwaar Saeed

Chinese Clinical Oncology · 2024

DOI: 10.21037/cco-24-28 ↗

Kurz gefasst

Editorial in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von James Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adenocarcinoma, Stomach Neoplasms, Esophagogastric Junction.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdenocarcinomaStomach NeoplasmsEsophagogastric JunctionB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesHumansEsophageal NeoplasmsBiomarkers, TumorAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Gastric cancerPD-L1gastro-esophageal junction cancer (GEJ cancer)pembrolizumabpredictive biomarker

Substanzen

Antibodies, Monoclonal, HumanizedB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorAntineoplastic Agents, ImmunologicalpembrolizumabCD274 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Zitieren

APA

Yu, J., & Saeed, A. (2024). PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811. Chinese Clinical Oncology. https://doi.org/10.21037/cco-24-28

Vancouver

Yu J, Saeed A. PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811. Chinese Clinical Oncology. 2024. doi:10.21037/cco-24-28

BibTeX
@article{Yu2024,
  author = {Yu, James and Saeed, Anwaar},
  title = {PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811},
  journal = {Chinese Clinical Oncology},
  year = {2024},
  doi = {10.21037/cco-24-28}
}
Kostenlos starten →